What Is Adipotide? Uses, Benefits, Safety, FDA Status, and Evidence

Medical review note: This article is for educational purposes only and does not provide medical advice. Adipotide is not FDA-approved for obesity, weight loss, cancer, diabetes, metabolic disease, bodybuilding, or any therapeutic use. Products sold online as Adipotide, FTPP, Prohibitin-TP01, TP01, fat-targeting peptide, proapoptotic peptide, or “research use only” Adipotide may carry serious safety, quality, legal, and regulatory risks.

Quick answer

Adipotide is an experimental proapoptotic peptidomimetic designed to target the blood vessels that supply white adipose tissue. It is also called FTPP, Prohibitin-TP01, TP01, or CKGGRAKDC-GG-D(KLAKLAK)2. Adipotide combines a white-fat vascular homing sequence with a proapoptotic sequence that can disrupt mitochondria and trigger cell death. In obese mice and rhesus monkeys, Adipotide caused weight loss, reduced body fat, and improved insulin-resistance markers. However, Adipotide is not FDA-approved, human efficacy data have not been established, a planned phase 1 prostate-cancer and obesity study appears to have been small and discontinued, and kidney toxicity was a major preclinical safety signal.

Key facts about Adipotide

What is Adipotide?

Adipotide is an experimental fat-targeting peptidomimetic. It was designed to attack the vascular supply of white adipose tissue rather than directly acting like a conventional appetite drug, GLP-1 receptor agonist, lipase inhibitor, or stimulant.

Adipotide is also known as:

• FTPP
• Prohibitin-TP01
• TP01
• CKGGRAKDC-GG-D(KLAKLAK)2

The structure is usually described as a fusion of two functional pieces:

1. A white-adipose-tissue homing sequence: CKGGRAKDC
2. A proapoptotic sequence: D(KLAKLAK)2

A PMC primate study described Adipotide as CKGGRAKDC-GG-D(KLAKLAK)2 and reported that it targeted white-adipose-tissue vasculature and caused weight loss in obese rhesus monkeys.

The key distinction:

Adipotide is not a normal weight-loss peptide. It is a vascular-targeted experimental compound designed to destroy part of the blood supply that supports white fat.

How does Adipotide work?

Adipotide’s proposed mechanism is vascular targeting plus apoptosis.

Research suggests that Adipotide binds targets associated with blood vessels supplying white adipose tissue, including prohibitin-associated vascular markers. After homing to this tissue, its proapoptotic D(KLAKLAK)2 sequence can disrupt mitochondria and trigger programmed cell death.

In plain English:

Adipotide tries to starve or destroy white fat by damaging the small blood vessels that feed it.

That is very different from drugs like semaglutide, tirzepatide, liraglutide, or dulaglutide, which affect appetite, glucose control, insulin secretion, and gut-hormone signaling.

Adipotide research discusses:

• White-adipose-tissue vascular targeting
• Prohibitin-associated targeting
• Endothelial-cell apoptosis
• Adipose-tissue blood-supply disruption
• Fat-cell loss after vascular injury
• Weight loss in obese animal models
• Improved insulin resistance markers in primates
• Kidney-toxicity concerns

This mechanism is powerful, but also risky.

A compound designed to kill targeted blood vessels cannot be assumed safe just because it causes fat loss.

What is Adipotide used for?

Adipotide is not approved for any use. It is an experimental compound.

| Use | Evidence level | What is known | What is not known | |---|---|---| | Obesity / weight loss | Preclinical evidence | Obese mice and rhesus monkeys lost weight in published studies. | Human weight-loss efficacy is not established. | | Insulin resistance | Preclinical primate evidence | Obese monkeys showed improved insulin-resistance markers after treatment. | Human diabetes or insulin-resistance benefit is not established. | | Type 2 diabetes | Preclinical / speculative | Improved metabolic markers in animals created interest. | It is not an approved diabetes treatment. | | Prostate cancer with obesity | Early clinical exploration | A phase 1 trial was cleared and initiated in obese patients with castrate-resistant prostate cancer. | No strong published clinical efficacy or safety data establish benefit. | | Body recomposition | Unsupported | Fat loss in animals attracts online interest. | Human consumer body-recomposition use is unproven and unsafe. | | Anti-aging / longevity | Unsupported | Weight loss can affect metabolic risk. | Adipotide is not an anti-aging therapy. | | Athletic cutting | Unsupported and high-risk | The mechanism could attract misuse. | It is not safe, approved, or appropriate for performance use. | | Online research-use Adipotide | High risk | Sold by some peptide vendors as FTPP or Adipotide. | Identity, purity, sterility, dose, toxicity, and legality may be unknown. |

What does the research show?

Preclinical obesity evidence

Adipotide’s strongest evidence is preclinical.

A PMC study in obese rhesus monkeys reported that Adipotide targeted white-fat vasculature and caused weight loss, reduced body fat, and improved insulin resistance. This study is the main reason Adipotide became widely discussed in obesity and peptide circles.

Earlier research on proapoptotic peptides targeting adipose vasculature described the broader strategy of reducing adipose tissue by attacking its vascular supply.

The practical interpretation:

Adipotide produced meaningful fat-loss effects in animal models, including nonhuman primates. That does not prove it is safe or effective in humans.

Kidney-toxicity signal

The most important safety issue in the primate literature is kidney toxicity.

The obese-monkey study reported renal effects as a dose-related toxicity concern. This matters because an obesity drug needs a very high safety bar. A compound that causes weight loss but creates kidney injury risk is not ready for routine human use.

The practical interpretation:

Adipotide’s kidney-toxicity signal is not a minor detail. It is one of the main reasons online “fat-loss peptide” claims are reckless.

Human clinical-trial context

Adipotide did reach early human-development planning.

Arrowhead announced that the FDA accepted an Investigational New Drug application allowing initiation of a phase 1 clinical trial. The planned study involved obese patients with castrate-resistant prostate cancer and no standard treatment options. The trial was intended to evaluate a 28-day treatment cycle, maximum tolerated dose, pharmacokinetics, weight change, and disease progression.

Arrowhead also announced dosing of the first patient in this phase 1 study.

However, this does not mean Adipotide became clinically proven. Publicly available information does not establish a completed, successful, peer-reviewed human efficacy dataset.

The practical interpretation:

Adipotide had clinical-development activity, but not enough published human evidence to support medical, obesity, or wellness use.

Prostate-cancer rationale

The prostate-cancer trial rationale was not simply “Adipotide treats cancer.” The logic was that adipose tissue can secrete factors that may support prostate cancer biology, so targeting adipose tissue in obese prostate-cancer patients might have disease relevance.

That is a hypothesis, not proof.

Adipotide is not an approved cancer therapy and should not be marketed as one.

Vascular-targeted therapy context

Reviews of vascular-targeted therapy discuss Adipotide as a promising but experimental prohibitin-targeting peptide. A PMC systems-biology review describes Adipotide as a vascular-targeted drug that showed rapid weight loss in mice.

The practical interpretation:

Adipotide is scientifically interesting as a targeted vascular-ablation strategy, but it remains experimental.

Evidence summary

Is Adipotide FDA-approved?

No. Adipotide is not FDA-approved.

There is no FDA-approved Adipotide product for:

• Obesity
• Weight loss
• Type 2 diabetes
• Insulin resistance
• Metabolic syndrome
• Prostate cancer
• Body recomposition
• Bodybuilding
• Athletic cutting
• Anti-aging
• General wellness
• Any human therapeutic use

The key distinction:

Adipotide had an FDA-cleared IND for early clinical testing, but IND clearance is not FDA approval.

Is Adipotide legal?

Adipotide’s legal status depends on country, product type, intended use, and whether it is part of an authorized clinical trial.

For U.S. readers:

Adipotide is not an FDA-approved drug, and online availability does not mean it is legally marketed for human therapeutic or weight-loss use.

Some sellers market Adipotide as FTPP, a fat-loss peptide, obesity peptide, or research-use peptide. That does not make it safe, approved, legal, or appropriate for consumer use.

The blunt version:

Buying “research use only” Adipotide online is not the same as receiving an FDA-approved obesity medication from a legitimate pharmacy.

Is Adipotide banned in sports?

I did not find Adipotide specifically named on the WADA prohibited list in the sources reviewed here.

However, Adipotide is not approved for human therapeutic use. WADA’s prohibited framework includes non-approved substances under S0, and athletes should treat unapproved experimental drugs as major anti-doping risks.

The WADA Prohibited List and USADA prohibited-list guidance should be checked directly.

The practical advice:

Athletes should avoid Adipotide and verify status through WADA, USADA, or Global DRO. An unapproved experimental fat-loss peptide is not a safe anti-doping choice.

Safety and side effects

Adipotide should be treated as high risk.

Possible or reported concerns include:

• Kidney toxicity
• Renal tubular injury concerns
• Increased creatinine or renal-function abnormalities
• Nausea
• Fatigue
• Injection-site reactions
• Off-target vascular effects
• Endothelial-cell toxicity
• Excessive or uncontrolled fat-tissue loss
• Unknown cardiovascular effects
• Unknown cancer-related effects
• Unknown reproductive safety
• Unknown long-term safety
• Unknown effects in people with kidney disease
• Product-quality and sterility risks from online sources
• Mislabeling or incorrect concentration
• Contamination risk
• Endotoxin risk
• Lack of medical supervision

The biggest issue is the mechanism.

Adipotide is designed to damage targeted blood vessels and induce apoptosis. That is not a low-risk wellness mechanism.

A serious evaluation should separate:

Adipotide vs similar obesity drugs and peptides

The key distinction:

Adipotide belongs in the adipose-vasculature ablation category, not the GLP-1, amylin, incretin, stimulant, or supplement category.

Why is Adipotide sold as “research use only”?

Some online sellers use “research use only” language to sell Adipotide outside normal drug channels.

That label is not a trust signal.

A serious reader should understand this distinction:

How to evaluate Adipotide claims online

Bottom line

Adipotide is an experimental fat-targeting proapoptotic peptidomimetic designed to attack the blood vessels supplying white adipose tissue. It produced weight loss and improved metabolic markers in obese animal models, including rhesus monkeys.

The most defensible conclusion is:

Adipotide is a scientifically interesting but high-risk experimental compound, not a proven human weight-loss therapy. It is not FDA-approved, human clinical evidence is lacking or unpublished, kidney toxicity is a major concern, and online Adipotide or FTPP products should not be treated as legitimate obesity medications.

FAQ

What is Adipotide?

Adipotide is an experimental proapoptotic peptidomimetic designed to target blood vessels supplying white adipose tissue.

What is FTPP?

FTPP is another name used for Adipotide. Adipotide is also called Prohibitin-TP01 or TP01.

What does Adipotide do?

Adipotide is designed to home to white-adipose-tissue blood vessels and deliver a proapoptotic sequence that disrupts mitochondria and triggers cell death in targeted vascular cells.

Is Adipotide FDA-approved?

No. Adipotide is not FDA-approved for obesity, weight loss, diabetes, cancer, body recomposition, anti-aging, or any other therapeutic use.

Does Adipotide cause weight loss?

Adipotide caused weight loss in obese animal models, including mice and rhesus monkeys. Human weight-loss efficacy is not established.

Is Adipotide the same as Ozempic?

No. Ozempic is semaglutide, a GLP-1 receptor agonist. Adipotide is a vascular-targeted proapoptotic compound.

Is Adipotide the same as tirzepatide?

No. Tirzepatide is a GIP and GLP-1 receptor agonist. Adipotide targets adipose-tissue vasculature.

Does Adipotide treat diabetes?

No. Adipotide is not an approved diabetes drug. Animal studies reported improved insulin-resistance markers, but human diabetes treatment evidence is not established.

Does Adipotide treat prostate cancer?

No approved evidence establishes Adipotide as a prostate-cancer treatment. A phase 1 study was initiated in obese patients with castrate-resistant prostate cancer, but no approved cancer indication exists.

Is Adipotide safe?

No reliable basis exists to call Adipotide safe for consumer use. Kidney toxicity was a major preclinical safety concern, and human safety data are not established.

Why is kidney toxicity a concern with Adipotide?

In obese rhesus monkey research, renal toxicity signals were reported. Because obesity drugs require long-term safety, kidney effects are a serious development concern.

Is Adipotide legal?

Adipotide is not an FDA-approved drug. Online sale as a research peptide does not mean it is legally marketed for human weight-loss or therapeutic use.

Is Adipotide banned in sports?

I did not find Adipotide specifically named on the WADA prohibited list in the sources reviewed here. However, because it is an unapproved experimental compound, athletes should assume major anti-doping risk and verify with WADA, USADA, or Global DRO.

Why do sellers call Adipotide “research use only”?

Sellers often use “research use only” language because Adipotide is not FDA-approved for consumer therapeutic use. The phrase does not make the product safe, legal, approved, or clinically proven.

What is the biggest risk with Adipotide?

The biggest risks are using an unapproved vascular-targeted proapoptotic compound without adequate human safety data, ignoring the kidney-toxicity signal, and buying online products with uncertain identity, purity, sterility, concentration, and safety.

Sources

1. PMC: A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys
2. PMC: Peptide Designed to Elicit Apoptosis in Adipose Tissue Endothelium
3. PMC: Systems Biology Will Direct Vascular-Targeted Therapy for Obesity
4. PMC: Vascular Targeted Nanotherapeutic Approach for Obesity Treatment
5. Arrowhead: FDA Clearance to Initiate Adipotide Phase 1 Clinical Trial
6. Arrowhead: Dosing of First Patient with Adipotide
7. Arrowhead SEC Filing: Adipotide Clinical Trial Context
8. PubMed: Comparative Study Between Nanoparticle-Targeted Therapeutics and Adipotide-Related Targeting
9. PMC: Targeted Proapoptotic Peptides Depleting Adipose Stromal and Perivascular Cells
10. PMC: Depletion of White Adipocyte Progenitors Induces Beige Adipocyte Expansion
11. WADA: Prohibited List
12. WADA: 2026 Prohibited List
13. USADA: WADA Prohibited List Guidance